Return to Home Page

View Cart (0) | Log In   
  
Search Learning Resources


CME Advisory Board
The CME Advisory Board guides and directs all of NEI's educational activities and CME policies. Our illustrious panel consists of top experts in the fields of continuing education, neuroscience, psychiatry, psychology, and psychopharmacology.

Master Psychopharmacologists
Brand new Master Psychopharmacologist Program coming soon!


Featured Articles
Alzheimer’s Disease: Current Therapeutic Status
By Israel Hanin, PhD
Awareness of Alzheimer’s disease (AD) and its prevalence in the aging population resurged about 40 years ago. Since then, research into the causes and possible cures associated with this disease has grown exponentially. Only five agents are FDA-approved for the treatment of AD patients in the U.S. Four of these are acetylcholinesterase inhibitors; one is an NMDA receptor antagonist. All of these are palliative at best. There presently is no definitive cure for AD. Investigators in the sphere of AD research are covering a broad spectrum of experimental targets, in an attempt to identify the cause of AD, to alleviate the symptoms of this disease state, to hopefully prevent further disease progression and, most importantly, to arrest it before it is able to infect the patient. Scientists from a broad spectrum of disciplines are involved in AD research, each approaching the subject matter from their unique perspective and experiences, thus providing a global and comprehensive overview of AD. Read more
Related: PsychEd Up | Invited Insights

The Brain Game: Circuits and Symptoms of Depression
This game will test your abilities at linking circuits to symptoms. Start playing! Read more
Related: PsychEd Up | Back to Basics

Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics?
By Stephen Stahl, MD, PhD
Although they’re pharmacologically interesting, dopamine D2 partial agonists might not be the best compounds to treat schizophrenia. It appears that only those on the antagonist end of the spectrum have antipsychotic efficacy, whereas those on the agonist end of the spectrum are less effective and can even be activating. It is important to get a better understanding of the pharmacological and clinical profiles of D2 partial agonists. Learning how to properly dose them and how to combine them in cases that necessitate polypharmacy might prove beneficial. Even if D2 partial agonists prove to be unpopular as a schizophrenia treatment, the novel pharmacological profile of these agents may have important clinical utility in mood disorders, and they may be effective as augmenting agents to reduce the side effects of D2 antagonists. One disorder’s trash is another disorder’s treasure. Read more
Related: PsychEd Up | Essential PsychopharmaSTAHLogy

Paroxetine
Dosing tips and prescribing pearls of paroxetine Read more
Related: PsychEd Up | Tips and Pearls

Mind Matters (Part II of II): An Exploration of the Placebo Effect in Treating Depression
By Christine Paczkowski, MS
It is well accepted that depression can occur when negative thought patterns alter brain chemistry, but what is the role of positive thought in pharmacological treatment of depression? This two-part article explores the psychological and pharmacological mechanisms underlying the placebo effect as a basis for considering the role of placebos in treating depression. Read more
Related: PsychEd Up | Second Messenger


 
Email Address
Password (Forgot password)
   Remember me
Featured Items
Announcing the 2008 Psychopharmacology Academy
The 2008 NEI Psychopharmacology Academies address clinically relevant advances in the research, diagnosis, and treatment of mental health disorders including psychosis, attention deficit hyperactivity disorder, treatment-resistant depression, comorbid psychiatric cases, and other clinical areas. More info



Announcing the 2008 Psychopharmacology Congress
Get ready for the Congress! Join us November 13-16, 2008 in Colorado Springs at The Broadmoor for four days of interactive learning. Register online today!

To contact customer service, technical support, or for more information: +1 888-535-5600 or info@neiglobal.com

    Bookmark This Page

Copyright © 2004-2008 Neuroscience Education Institute. All rights reserved.
Home   About Us   Become A Member   Contact Us   Privacy Statement   Submit Feedback
Information is subject to change. Best viewed with Internet Explorer 6.

03 July 2008